QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.
Follow QGEN
QIAGEN N.V. (QGEN) P/E ratio
As of 16 October 2026, QIAGEN N.V. (QGEN) trades at a P/E ratio of 23.6×. Over the past ten years it has ranged from 0.0× (June 2020) to 1,610× (August 2020); the current reading is higher than 27% of that period. That is below the Diagnostics & Research industry median of 35.6× and in line with the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.3× | (81.07%) |
| FY2024 | 118× | 328.33% |
| FY2023 | 27.5× | 9.62% |
| FY2022 | 25.1× | 7.90% |
| FY2021 | 23.3× | (27.18%) |
| FY2020 | 31.9× | — |
| FY2019 | 0.0× | — |
| FY2018 | 38.8× | (77.22%) |
| FY2017 | 170× | 114.43% |
| FY2016 | 79.5× | 64.68% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 20.0× | (4.19%) |
| Mar 2026 | 20.9× | (6.24%) |
| Dec 2025 | 22.3× | (3.32%) |
| Sep 2025 | 23.1× | (14.48%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| CRL Charles River Laboratories International, Inc. compare | n/m |
| RDNT RadNet, Inc. compare | n/m |
| GRAL GRAIL, Inc. compare | n/m |
| QGEN QIAGEN N.V. | 23.6× |
| SHC Sotera Health Company compare | 31.4× |
| MEDP Medpace Holdings, Inc. compare | 35.6× |
| RVTY Revvity Inc. compare | 72.7× |
| ICLR ICON PLC compare | 254× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)